XY Therapeutics ApS: Financial statements 2022
CVR: 41120681
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
XY Therapeutics ApS (CVR 41120681) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 626,764 and a net result of DKK -2,384,371. Equity in the 2022 report amounted to DKK -4,875,587. The company had 2 employees in the financial year.
- Gross Profit
- DKK 626,764
- Profit/Loss
- DKK -2,384,371
- Equity
- DKK -4,875,587
- Total Assets
- DKK 5,347,874
- Employees
- 2
Official annual report
Keep an eye on XY Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout XY Therapeutics ApS
XY Therapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Fertilitypro ApS. The management consists of Martin Blomberg Jensen. The company is owned by Holding Fertility4U ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,676,788 and a net result of DKK -2,096,400 compared with DKK -1,369,854 the year before. Equity in the 2025 report amounted to DKK -9,494,046.